Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지

Haemophilus influenzae type b(Hib) 백신 접종의 현황과 전망

Present status and prospects of Haemophilus influenzae type b(Hib) immunization

  • 김경효 (이화여자대학교 의과대학 소아과학교실)
  • Kim, Kyung Hyo (Department of Pediatrics, College of Medicine, Ewha Woman's University)
  • 투고 : 2006.02.08
  • 심사 : 2006.02.10
  • 발행 : 2006.03.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Haemophilus influenzae type b(Hib) conjugate vaccines prevent Hib disease in individuals and reduce the carriage and transmission of the organism in the community. The incidence of Hib disease has been decreased dramatically in a diverse range of countries through the use of a variety of conjugate vaccines and vaccine schedules. In some countries, the vaccine has caused a near-disappearance of invasive Hib disease through a combination of direct protection and herd immunity. The effectiveness of the vaccine was not modified by the type of conjugate vaccine, the number of doses given(two, three or four), age at first vaccination(two months, 42 to 90 days, three months) and whether the vaccine was tested in an industrialized or developing country. Over 15 years of international experience with vaccines has also demonstrated that they are safe. In 2004, Hib vaccines were adapted in routine immunization in 92 countries in the world. Decisions regarding the use of the Hib vaccine in routine immunization schedules depend not only on the effectiveness and efficacy of the vaccine but also on factors such as burden of disease, vaccine cost, and competing priorities. In Korea, Hib disease burden seemed to be lower than other developed countries(~10/100,000). Moreover Hib vaccines showed excellent immunogenicity in Korean children in many studies. Therefore, a potential approach to economize the cost of Hib vaccines could be to explore the possibilities of using reduced vaccine doses for immunization as some other countries.

키워드

참고문헌

  1. Pittman M. Variation and type specificity in the bacterial species H. influenzae. J Exp Med 1931;53:471-95 https://doi.org/10.1084/jem.53.4.471
  2. Winslow CE, Broadhurst J, Buchanan RE. The families and genera of the bacteria : Final report of the committee of the Society of American Bacteriologists on characterization and classification of bacterial types. In : Plotkin SA, Mortimer EA, editors. Vaccines. 2nd ed, Philadelphia : WB Saunders Co, 1994:337-86
  3. Fothergill LD, Wright J. Influenzal meningitis : The regulation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933;24:273-84
  4. Wenger JD, Ward JI. Haemophilus influenzae vaccine. In : Plotkin SA, Orenstein WA, editors. Vaccines. 4th ed. Philadelphia : WB Saunders Co, 2004:229-68
  5. infections. In : Pickering LK, editor. 2003 Red book : Report of the Committee on infectious diseases. 26th ed. Elk Grove Village, 2003:293-301
  6. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century : Global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev 2000;13:302-17 https://doi.org/10.1128/CMR.13.2.302-317.2000
  7. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease : what are the next steps? Proceedings of the meeting Scottsdale, Arizona, September 22-25, 2002
  8. Watt JP, Levine OS, Santosham M. Global reduction of Hib disease : what are the next steps? J Pediatr 2003;143(6 Suppl):S163-87
  9. Decker MD, Edwards KM, Bradley R, Palmer P. Comparative trial in infants of four conjugate Haemophilus influenzae type b vaccines. J Pediatr 1992;120:184-9 https://doi.org/10.1016/S0022-3476(05)80424-X
  10. Granoff DM, Anderson EL, Osterholm MT, Holmes SJ, McHugh JE, Belshe RB, et al. Differences in the immunogenicity of three Haemophilus influenzae type b conjugate vaccines in infants. J Pediatr 1992;121:187-94 https://doi.org/10.1016/S0022-3476(05)81186-2
  11. Kayhty H, Eskola J, Peltola H, Ronnberg PR, Kela E, Karanko V, et al. Antibody responses to four Haemophilus influenzae type b conjugate vaccines. Am J Dis Child 1991;145:223-7
  12. Bulkow LR, Wainwright RB, Letson GW, Chang SJ, Ward JI. Comparative immunogenicity of four Haemophilus influenzae type b conjugate vaccines in Alaska Native infants. Pediatr Infect Dis J 1993;12:484-92 https://doi.org/10.1097/00006454-199306000-00006
  13. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, et al. A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990;323:1381-7 https://doi.org/10.1056/NEJM199011153232004
  14. Eskola J, Takala AK, Kayhty H. Haemophilus influenzae type b polysaccharide-protein conjugate vaccines in children. Curr Opin Pediatr 1993;5:55-9 https://doi.org/10.1097/00008480-199302000-00009
  15. Ramsay ME, McVernon J, Andrews NJ, Heath PT, Slack MP. Estimating Haemophilus influenzae type b vaccine effectiveness in England and Wales by use of the screening method. J Infect Dis 2003;188:481-5 https://doi.org/10.1086/376997
  16. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type b infections. The Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No. : CD001729. DOI : 10.1002/14651858.CD001729
  17. Broome CV. Epidemiology of Haemophilus influenzae type b infections in the United States. Pediatr Infect Dis J 1987;6:779-82 https://doi.org/10.1097/00006454-198708000-00036
  18. Makela PH, Takala AK, Peltola H, Eskola J. Epidemiology of invasive Haemophilus influenzae type b disease. J Infect Dis 1992;165(Suppl 1):S2-6 https://doi.org/10.1093/infdis/165.Supplement_1-S2
  19. Gervaix A, Suter S. Epidemiology of invasive Haemophilus influenzae type b infections in Geneva, Switzerland, 1976 to 1989. Pediatr Infect Dis J 1991;10:370-4 https://doi.org/10.1097/00006454-199105000-00005
  20. Gilbert GL, Clements DA, Broughton SJ. Haemophilus influenzae type b infections in Victoria, Australia, 1985 to 1987. Pediatr Infect Dis J 1990;9:252-7. https://doi.org/10.1097/00006454-199004000-00006
  21. Phipps DC, West J, Eby R, Koster M, Madore DV, Quataert SA. An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay. Immunol Methods 1990;135:121-8 https://doi.org/10.1016/0022-1759(90)90264-V
  22. Madore DV, Anderson P, Baxter BD, Carlone GM, Edwards KM, Hamilton RG, et al. Interlaboratory study evaluating quantitation of antibodies to Haemophilus influenzae type b polysaccharide by enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 1996;3:84-8
  23. Vaccine Assessment Monitoring Team. WHO vaccine-preventable diseases : monitoring system, 2004 global summary. WHO Department of Immunization, Vaccines and Biologicals. WHO document production services, Geneva, Switzerland
  24. Cochi SL, Fleming DW, Hightower AW, Limpakarnjanarat K, Facklam RR, Smith JD, et al. Primary invasive Haemophilus influenzae type b disease : a population-based assessment of risk factors. J Pediatr 1986;108:887-96 https://doi.org/10.1016/S0022-3476(86)80922-2
  25. Coulehan JL, Michaels RH, Hallowell C, Schults R, Welty TK, Kuo JS. Epidemiology of Haemophilus influenzae type B disease among Navajo Indians. Public Health Rep 1984; 99:404-9.
  26. Losonsky GA, Santosham M, Sehgal VM, Zwahlen A, Moxon ER. Haemophilus influenzae disease in the White Mountain Apaches : molecular epidemiology of a high risk population. Pediatr Infect Dis 1984;3:539-47 https://doi.org/10.1097/00006454-198411000-00012
  27. Ward JI, Lum MK, Hall DB, Silimperi DR, Bender TR. Invasive Haemophilus influenzae type b disease in Alaska : background epidemiology for a vaccine efficacy trial. J Infect Dis 1986;153:17-26. https://doi.org/10.1093/infdis/153.1.17
  28. Santosham M, Wolff M, Reid R, Wolff M, Reid R, Hohenboken M, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type bpolysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991;324:1767-72 https://doi.org/10.1056/NEJM199106203242503
  29. Harrison LH, Tajkowski C, Croll J, Reid R, Hu D, Brenneman G, et al. Post licensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children. J Pediatr 1994;125:571-6 https://doi.org/10.1016/S0022-3476(94)70009-5
  30. Black SB, Shinefield HE, Fireman B, Hiatt R, Polen M, Vittinghof E, The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J 1991;10:97-104 https://doi.org/10.1097/00006454-199102000-00004
  31. Fritzell B, Plotkin S. Efficacy and safety of a Haemophilus influenzae type b capsular polysaccharide-tetanus protein conjugate vaccine. J Pediatr 1992;121:355-62 https://doi.org/10.1016/S0022-3476(05)81786-X
  32. Booy R, Hodgson S, Carpenter L, Mayon-White RT, Slack MP, Macfarlane JA, et al. Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T. Lancet 1994;344:362-6 https://doi.org/10.1016/S0140-6736(94)91400-1
  33. Makela PH, Peltola H, Kayhty H, Jousimies H, Pettay O, Ruoslahti E, et al. Polysaccharide vaccines of group A Neisseria meningtitidis and Haemophilus influenzae type b : a field trial in Finland. J Infect Dis 1977;136 Suppl:S43-50 https://doi.org/10.1093/infdis/136.Supplement.S43
  34. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis 1983;147:1100 https://doi.org/10.1093/infdis/147.6.1100
  35. Makela PH, Eskola J, Peltola H, Takala AK, Kayhty H. Clinical experience with Haemophilus influenzae type bconjugate vaccines. Pediatrics 1990;85:651-3
  36. Eskola J, Peltola H, Takala AK, Kayhty H, Hakulinen M, Karanko V, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987;317:717-22 https://doi.org/10.1056/NEJM198709173171201
  37. Peltola H, Eskola J, Kayhty H, Takala AK, Makela H. Clinical comparison of the Haemophilus influenzae type B polysaccharide-diphtheria toxoid and the oligosaccharide-CRM197 protein vaccines in infancy. Arch Pediatr Adolesc Med 1994;148:620-5 https://doi.org/10.1001/archpedi.1994.02170060074015
  38. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunization with conjugate vaccines. Lancet 1992;340:592-4 https://doi.org/10.1016/0140-6736(92)92117-X
  39. Takala AK, Eskola J, Leinonen M, Kayhty H, Nissinen A, Pekkanen E, et al. Reduction of oropharyngeal carriage of Haemophilus influenzae type b(Hib) in children immunized with an Hib conjugate vaccine. J Infect Dis 1991;164:982-6 https://doi.org/10.1093/infdis/164.5.982
  40. Peltola H. Haemophilus influenzae type b disease and vaccination in Europe : lessons learned. Pediatr Infect Dis J 1998;17(9 Suppl):S126-32 https://doi.org/10.1097/00006454-199809001-00007
  41. Eskola J, Takala A, Kayhty H, Peltola H, Makela PH. Experience in Finland with Haemophilus influenzae type b vaccines. Vaccine 1991;9 Suppl:S14-6 https://doi.org/10.1016/0264-410X(91)90174-5
  42. Schmitt HJ, Zepp F, Muschenborn S, Sumenicht G, Schuind A, Beutel K, et al. Immunogenicity and reactogenicity of a Haemophilus influenzae type b tetanus conjugate vaccine when administered separately or mixed with concomitant diphtheria-tetanus-toxoid and acellular pertussis vaccine for primary and for booster immunizations. Eur J Pediatr 1998;157:208-14 https://doi.org/10.1007/s004310050797
  43. Lagergard T, Taranger J, et al. Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate. J Pediatr 1989;114:97-100 https://doi.org/10.1016/S0022-3476(89)80611-0
  44. Knutsson N, Trollfors B, Taranger J, Bergfors E, Sundh V, Lagergard T, et al. Immunogenicity and reactogenicity of diphtheria, tetanus and pertussis toxoids combined with inactivated polio vaccine, when administered concomitantly with or as a diluent for a Hib conjugate vaccine. Vaccine 2001;19:4396-403 https://doi.org/10.1016/S0264-410X(01)00199-2
  45. Dagan R. A two-year prospective, nationwide study to determine the epidemiology and impact of invasive childhood Haemophilus influenzae type b infection in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. Clin Infect Dis 1992;15:720-5. https://doi.org/10.1093/clind/15.4.720
  46. Dagan R, Fraser D, Roitman M, Slater P, Anis E, Ashkenazi S, et al. Effectiveness of a nationwide infant immunization program against Haemophilus influenzae b. The Israeli Pediatric Bacteremia and Meningitis Group. Vaccine 1999;17:134-41 https://doi.org/10.1016/S0264-410X(98)00165-0
  47. Bijlmer HA, van Alphen L, Greenwood BM, Brown J, Schneider G, Hughes A, et al. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in The Gambia, West Africa. J Infect Dis 1990;161:1210-5 https://doi.org/10.1093/infdis/161.6.1210
  48. Mulholland EK, Byass P, Campbell H, Fritzell B, Greenwood AM, Todd J, et al. The immunogenicity and safety of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine in Gambian infants. Ann Trop Paediatr 1994;14:183-8 https://doi.org/10.1080/02724936.1994.11747715
  49. Mulholland EK, Ahonkhai VI, Greenwood AM, Jonas LC, Lukacs LJ, Mink CM, et al. Safety and immunogenicity of Haemophilus influenzae type B-Neisseria meningitidis group B outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 1993; 12:632-7 https://doi.org/10.1097/00006454-199308000-00002
  50. Mulholland EK, Hoestermann A, Ward JI, Maine N, Ethevenaux C, Greenwood BM. The use of Haemophilus influenzae type b-tetanus toxoid conjugate vaccine mixed with diphtheria-tetanus-pertussis vaccine in Gambian infants. Vaccine 1996;14:905-9. https://doi.org/10.1016/0264-410X(95)00260-8
  51. Mulholland K, Hilton S, Adegbola R, Usen S, Oparaugo A, Omosigho C, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine for prevention of pneumonia and meningitis in Gambian infants. Lancet 1997;349:1191-7 https://doi.org/10.1016/S0140-6736(96)09267-7
  52. Wenger JD. Epidemiology of Haemophilus influenzae type b disease and impact of Haemophilus influenzae type b conjugate vaccines in the United States and Canada. Pediatr Infect Dis J 1998;17(9 Suppl):S132-6 https://doi.org/10.1097/00006454-199809001-00008
  53. Cho JB, Chang SH, Kum DH, Kang JM, Shin DH. A clinical observation on purulent meningitis in infancy and childhood. J Korean Pediatr Soc 1972;15:54-62
  54. Lee SH, Yun DJ. Clinical studies of purulent meningitis in infants and children. J Korean Pediatr Soc 1976;18:36-43
  55. Chang SH, Kim YG, Lim BK, Kim JS. Clinical studies of purulent meningitis in infant and children. J Korean Pediatr Soc 1983;25:304-14
  56. Kim KH, Sohn YM, Kang JH, Kim KN, Kim DS, Kim JH, et al. The causative organisms of bacterial meningitis in Korean children, 1986-1995. J Korean Med Sci 1998;13:60-4
  57. Kim JS, Jang YT, Kim JD, Park TH, Park JM, Kilgore PE, et al. Incidence of Haemophilus influenzae type b and other invasive diseases in South Korean children. Vaccine 2004;22:3952-62 https://doi.org/10.1016/j.vaccine.2004.04.003
  58. Committee on Infectious Diseases, Korean Pediatric Association. Haemophilus influenzae type b(Hib). Recommendations of the advisory committee on immunization practices. 5th ed, Korean Pediatric Association, 2002:163-80
  59. Ward J, Brenneman G, Letson GW, Heyward WL, The Alaska H. influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska native infants. N Engl J Med 1990;323:1393-401 https://doi.org/10.1056/NEJM199011153232006
  60. Granoff DM, Holmes SJ. G2m(23) immunoglobulin allotype and immunity to Haemophilus influenzae type b. J Infect Dis 1992;165:S66-7 https://doi.org/10.1093/infdis/165-Supplement_1-S66
  61. Granoff DM, Suarez BK, Pandey JP, Shackelford PG. Genes associated with the G2m(23) immunoglobulin allotype regulate the IgG subclass responses to Haemophilus influenzae type b polysaccharide vaccine. J Infect Dis 1988; 157:1142-9 https://doi.org/10.1093/infdis/157.6.1142
  62. Pwrwesen GM, Silimperi DR, Rotter JI, Terasaki PI, Schanfield MS, Park MS, et al. Genetic factors in Haemophilus influenzae type b disease susceptibility and antibody acquisition. J Pediatr 1987;110:228-33 https://doi.org/10.1016/S0022-3476(87)80159-2
  63. Anderson P, Insel RA. Prospects for overcoming maturational and genetic barriers to the human antibody response to the capsular polysaccharide of Haemophilus influenzae type b. Vaccine 1988;6:188-91 https://doi.org/10.1016/S0264-410X(88)80026-4
  64. Cryz J, Furer E, Fredeking T, Cross AS, Sadoff JC, Que JU. Effect of race and blood group on the immune response to bacterial polysaccharide and conjugate vaccines. Lancet 1989;23:1533-4
  65. Lee HJ, Kim CH, Park CY, Shon YM, Oh SH, Chun CS, et al. Natural antibody against Haemophilus influenzae type b in a sample population of Korean children. J Korean Pediatr Soc 1993;36:1471-7
  66. Yoo ES, Park EA, Kim GH. Natural anti-PRP antibody level to Haemophilus influenza type b(hib) and change of antibody level after three doses of vaccination. J Korean Pediatr Soc 1995;38:1201-9.
  67. Kim JS, Cho SB, Lee HR, Park SK, Hwang PH. Immunogenicity and safety of Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine(PRP-T) in Korean infants. Korean J Infect Dis 1996;28:225-32 https://doi.org/10.3109/00365549609027161
  68. Choi SY, Kim HT, Kim YW, Kang YJ, Chung YC, Chang JK, et al. Immunogenicity of Haemophilus influenzae PRPD conjugate vaccine in Korean infants. J Korean Pediatr Soc 1999;42:771-7
  69. Yang PS, Seo JI, Noh KT, Yoo JH, Hwang KS, Hwang KG. Studies of the change of antibody titers after vaccination of Haemophilus influenzae PRP-T conjugate vaccine. J Korean Pediatr Soc 2002;45:987-93
  70. Chung EH, Kim YJ, Kim YK, Kim DH, Seo JW, Lee HJ. Immunogenicity and safety of a Haemophilus influenzae type b polysaccharide-tetanus toxoid conjugate vaccine (PRP-T; $Hiberix^{TX}$) in Korean infants. J Korean Pediatr Infect Dis 2003;10:71-80 https://doi.org/10.14776/kjpid.2003.10.1.71
  71. Kim KH, Kang JH, Kim JS, Kim JH, Park SE, Park EA, et al. A study for immunization schedule assessment of Hib vaccine in Korea. Program and Abstract. the 55th Annual Fall Meeting of the Korean Pediatric Society; 2005 Oct 21-22; Seoul. Seoul : The Korean Pediatric Society, 2005:68
  72. Lagos R, Valenzuela MT, Levine OS, Losonsky GA, Erazo A, Wasserman SS, et al. Economisation of vaccination against Haemophilus influenzae type b : a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet 1998;351:1472-6 https://doi.org/10.1016/S0140-6736(97)07456-4
  73. Black SB, Shinefield HR, Ray P, Lewis EM, Fireman B, Hiatt R, et al. Safety of combined oligosaccharide conjugate Haemophilus influenzae type b(HbOC) and whole cell diphtheria- tetanus toxoids-pertussis vaccine in infancy. The Kaiser Permanente Pediatric Vaccine Study Group. Pediatr Infect Dis J 1993;12:981-5 https://doi.org/10.1097/00006454-199312000-00003
  74. Pichichero ME, Latiolais T, Bernstein DI, Hosbach P, Christian E, Vidor E, et al. Vaccine antigen interactions after a combination diphtheria-tetanus toxoid-acellular pertussis/purified capsular polysaccharide of Haemophilus influenzae type b-tetanus toxoid vaccine in two-, four- and six-month-old infants. Pediatr Infect Dis J 1997;16:863-70 https://doi.org/10.1097/00006454-199709000-00009
  75. West DJ, Hesley TM, Jonas LC, Feeley LK, Bird SR, Burke P, et al. Safety and immunogenicity of a bivalent Haemophilus influenzae type b/hepatitis B vaccine in healthy infants. Hib-HB Vaccine Study Group. Pediatr Infect Dis J 1997;16:593-9 https://doi.org/10.1097/00006454-199706000-00010
  76. Fagnani F, Le Fur C, Durand I, Gibergy M. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. Eur J Health Econ 2004;5:143-9
  77. Nolan T, Altmann A, Skeljo M, Streeton C, Schuerman L. Antibody persistence, PRP-specific immune memory, and booster responses in infants immunised with a combination DTPa-HBV-IPV/Hib vaccine. Vaccine 2004;23:14-20 https://doi.org/10.1016/j.vaccine.2004.06.017